First human tests of a non-hormonal male contraceptive pill show promising results, raising hopes for a safer and more equal approach to birth control.
A new type of male contraceptive has shown promising early results in its first human trial. The pill, known as YCT-529, does not rely on artificial hormones and so far appears to avoid the side effects that have caused earlier versions to fail. If further trials go well, it could become the first non-hormonal, reversible contraceptive for men to reach the market.
Sixteen healthy men took part in the first-stage clinical trial, which tested the pill’s safety and monitored its effects on hormone levels, organ function, heart rhythm, mood, and sexual desire. None of the participants experienced serious side effects, and researchers say the drug was well tolerated across different doses. The next step will be larger and longer trials to test how well the drug works at preventing pregnancy.
At the moment, men have just two main options for contraception: condoms, which are widely available but can fail, and vasectomy, which is highly effective but usually permanent. Previous attempts to develop male contraceptive drugs have often been abandoned due to serious side effects. Most used hormones to stop sperm production, but this also lowered testosterone, which led to symptoms like mood swings, acne, and reduced sex drive. These side effects were often considered unacceptable, even though many women routinely manage similar or worse effects from contraceptive methods available to them.
This new drug works differently. Instead of changing hormone levels, it targets a protein in the testes called retinoic acid receptor alpha. In animal tests, blocking this receptor stopped sperm production temporarily without changing testosterone levels. When the drug was stopped, fertility returned, and the animals went on to have healthy offspring. This gives researchers hope that the method could offer temporary and reversible contraception without the usual drawbacks.
The human trial was short – participants were only monitored for 15 days – and not designed to measure how effective the drug is at preventing pregnancy. But early results showed no changes in testosterone, and no issues with liver or kidney function. The participants reported no major changes in mood or sexual desire. There were also no signs of serious side effects like irregular heart rhythms or cell damage.
The company behind the drug has now started phase two trials, which will include more participants and longer follow-up periods. If those are successful, a third phase involving hundreds of men will be needed to test how effective and reversible the drug is in real-world use. These later stages are often where new contraceptives run into difficulties, and there is still a long way to go before the pill could be approved for use.
Still, the early signs are encouraging. For decades, the burden of long-term contraception has largely fallen on women, who often deal with side effects, daily routines, and invasive procedures. Campaigners have long argued that more should be done to give men a meaningful role in pregnancy prevention beyond condoms or surgery.
Whether this new drug can change that will depend on how the next stages go – and how willing the pharmaceutical industry is to invest in a method that could shift some of the responsibility for contraception. For now, though, YCT-529 offers a rare sign of progress in an area that has seen years of false starts and limited options.
